Journal of Ocular Pharmacology and Therapeutics 2013-09-01

Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.

Anastasios G P Konstas, Gábor Holló, Anna-Bettina Haidich, Dimitrios G Mikropoulos, Theodoros Giannopoulos, Irini C Voudouragkaki, Eleni Paschalinou, Vassilios Konidaris, John R Samples

Index: J. Ocul. Pharmacol. Ther. 29(7) , 652-7, (2013)

Full Text: HTML

Abstract

To determine the adjunctive 24-h efficacy obtained with brinzolamide/timolol, or brimonidine/timolol fixed combinations (FCs) in open-angle glaucoma patients insufficiently controlled on travoprost monotherapy.Prospective, observer-masked, active controlled, crossover, comparison. Qualified primary open-angle or exfoliative glaucoma patients with a baseline intraocular pressure (IOP) >18 mm Hg at 10:00 on travoprost monotherapy were randomized for 3 months to either brinzolamide/timolol, or brimonidine/timolol FC therapy adjunct to travoprost. Patients were then crossed-over to the opposite therapy for another 3 months. At baseline and at the end of each treatment period, the patients underwent 24-h IOP monitoring.Fifty patients completed the study. The mean 24-h baseline IOP on travoprost monotherapy was 20.1 mm Hg [95% confidence interval (CI): 19.6, 20.7 mm Hg]. Both adjunctive FC therapies significantly reduced the IOP at each time point and for the mean 24-h IOP (P<0.001) compared with travoprost monotherapy. Brinzolamide/timolol FC provided a significantly lower mean 24-h IOP (17.2 mm Hg, 95% CI: 16.4, 17.9 mm Hg) than brimonidine/timolol FC (18.0 mm Hg, 95% CI: 17.3, 18.8 mm Hg) (P<0.001). For all the 3 timepoints between 18:00 and 02:00, the brinzolamide/timolol FC provided a significantly lower IOP than the brimonidine/timolol FC (P≤0.036). For the other 3 timepoints, no significant differences were detected.This study demonstrated that both FCs provide statistically and clinically significant incremental 24-h IOP lowering to travoprost monotherapy. The brinzolamide/timolol FC however achieves a better mean 24-h IOP control owing to the greater efficacy in late afternoon and during the night.


Related Compounds

Related Articles:

Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.

2014-09-01

[J. Liposome Res. 24(3) , 171-81, (2014)]

Soluble CD44 and vascular endothelial growth factor levels in patients with acute primary angle closure.

2015-06-01

[Acta Ophthalmol. 93 , e261-5, (2015)]

Meta-analysis of α2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy.

2012-04-01

[Curr. Med. Res. Opin. 28(4) , 543-50, (2012)]

Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.

2010-11-01

[Curr. Med. Res. Opin. 26(11) , 2575-8, (2010)]

Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.

2011-07-01

[Graefes Arch. Clin. Exp. Ophthalmol. 249(7) , 1065-71, (2011)]

More Articles...